RVTY

Revvity, Inc.

HealthcareDiagnostics & ResearchNASDAQ

$104.55

+$10.05 (9.61%)today

Conviction

4/ 10

Fair Value$118.27

Upside+13.12%

Signal5.25

Market Cap$9.7B

52W Range$81.36–$118.30

Next EarningsApr 27

Conviction History

Conviction Changes

Mar 26, 2026, 2:05 PM3→4daily-review

Mar 19, 2026, 1:07 AM5→3conviction-rescore

Premium Content

Upgrade to premium to see the full reasoning behind each conviction change.

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$53.16

Current Price$85.94

Upside / Down-38.1%

P(Undervalued)0.9%

P(20%+ Up)0.0%

P(15%+ Down)92.6%

Fair Value Distribution — percentile bands

0.9% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

9.9%/yr

±4.5% · revenue growth to justify current price

FCF-Based Reverse DCF

15.0%/yr

±3.0% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

analysisMar 26

Conviction: unchanged

RVTY Q4 2025 & 2026 Guidance: Destocking Cycle Over, But 2-3% Organic Growth Is a Low Bar

Q4 2025 beat: revenue M (+6% reported, +4% organic) vs M consensus. 2026 guide: .96-2.99B revenue, adj EPS .35-.45 (beat consensus .32). Biopharma destocking cycle ending; demand returning. But 2-3% o...

sec_10kMar 4

Conviction: unchanged

RVTY FY2025: Weak revenue growth, tariff headwinds, margin compression despite cost cuts

RVTY FY2025 reveals slowing growth (4% revenue) against backdrop of tariff headwinds ($25M cost), margin compression (gross margin -104 bps), and inventory/working capital normalization. Life Sciences...